A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06994806 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Malignancies

Interventions

DRUG: KQB168
DRUG: Pembrolizumab

Sponsor

Kumquat Biosciences Inc.